Opinion
Video
CheckMate 77T: Perioperative Immunotherapy in Resectable NSCLC
Patrick Forde, MBBCh, shares insights on perioperative immunotherapy in the CheckMate-77T study presented at ESMO 2023.
This is a video synopsis/summary of a Post Conference Perspectives involving Patrick Forde, MBBCh.
In this video, Forde discusses recent advances in the treatment of non–small cell lung cancer (NSCLC). He notes that over the past decade, management of NSCLC has dramatically changed with the introduction of targeted therapies and immunotherapy. NSCLC can be characterized by targetable molecular alterations for first-line therapy in advanced disease. However, many patients still do not respond to initial therapies. Addition of systemic therapy in early-stage, surgically resectable disease is also an unmet need.
Forde discusses results from CheckMate-77T (NCT04025879), the third trial of perioperative immunotherapy in NSCLC. In this phase 3 trial, 461 patients with stage II to IIIB NSCLC without targetable mutations were randomly assigned 1:1 to neoadjuvant nivolumab (anti–PD-1) with platinum-doublet chemotherapy followed by surgery and adjuvant nivolumab, or placebo with platinum-doublet chemotherapy followed by surgery and adjuvant placebo. The majority underwent planned surgery. The study met its primary end point, with nivolumab significantly improving event-free survival and pathologic complete response rate.
Forde notes this is the third positive trial showing benefit of perioperative immunotherapy in NSCLC. Results support moving away from postoperative therapy alone to strongly considering neoadjuvant immunotherapy plus adjuvant therapy for NSCLC. Data from other cancers suggest potential benefit from the neoadjuvant phase.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
